Oncology Medicines - Olaparib Olanib 50mg Exporter from Mumbai
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer | Clinical Cancer Research
Pharmaceutical Capsule - Sutent Capsule Wholesale Trader from Bengaluru
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors - ScienceDirect
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial - The Lancet Oncology
US OKs 1st drug aimed at women with inherited breast cancer
EP3263095A1 - A pharmaceutical formulation of olaparib - Google Patents
PARP inhibitors in ovarian cancer
PDF) PARP inhibitors in ovarian cancer
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYNPARZA safely and effe
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
PDF) Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer
Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells | Molecular Cancer Research
PARP and PARG inhibitors in cancer treatment. - Abstract - Europe PMC
OSIMERT 80 MG (OSIMERTINIB) - Saif pharma
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer: Expert Opinion on Pharmacotherapy: Vol 0, No ja
pCODR EXPERT REVIEW COMMITTEE (pERC) FINAL RECOMMENDATION
Role of PARP Inhibitors in BRCA-Related Malignancies
Cancers | Free Full-Text | Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes | HTML
Targeting DNA damage in SCLC - Lung Cancer
您需要了解的LYNPARZA癌症知识- 医- 2021
Genes | Free Full-Text | MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer | HTML
Role of PARP Inhibitors in BRCA-Related Malignancies